Last reviewed 2026-04-22 · How we verify

Anti-Human Thymocyte Immunoglobulin, Rabbit

Anti-Human Thymocyte Immunoglobulin, Rabbit is a Polyclonal antithymocyte immunoglobulin Small molecule drug developed by Peking Union Medical College Hospital. It is currently FDA-approved for Prevention of acute organ rejection in allogeneic transplantation, Treatment of aplastic anemia, Graft-versus-host disease (GVHD) prophylaxis and treatment. Also known as: ATG.

This rabbit-derived polyclonal antibody depletes T lymphocytes by binding to antigens on human thymocytes and T cells, thereby suppressing the immune response.

This rabbit-derived polyclonal antibody depletes T lymphocytes by binding to antigens on human thymocytes and T cells, thereby suppressing the immune response. Used for Prevention of acute organ rejection in allogeneic transplantation, Treatment of aplastic anemia, Graft-versus-host disease (GVHD) prophylaxis and treatment.

At a glance

Mechanism of action

Anti-human thymocyte immunoglobulin (ATG) is a polyclonal antibody preparation derived from immunized rabbits that targets multiple epitopes on human T lymphocytes and thymocytes. It causes T-cell depletion through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, resulting in profound immunosuppression. This mechanism makes it useful in preventing graft rejection and treating conditions driven by pathogenic T cells.

Approved indications

• Prevention of acute organ rejection in allogeneic transplantation
• Treatment of aplastic anemia
• Graft-versus-host disease (GVHD) prophylaxis and treatment

Common side effects

• Fever and chills
• Thrombocytopenia
• Leukopenia
• Serum sickness
• Infection (due to immunosuppression)
• Cytokine release syndrome

Key clinical trials

• A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
• Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
• Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Infertility (NA)
• Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
• A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
• Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (PHASE2)
• Immune Tolerance Induction After Liver Transplantation (PHASE1, PHASE2)
• Allo HSCT for High Risk Hemoglobinopathies (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Anti-Human Thymocyte Immunoglobulin, Rabbit CI brief — competitive landscape report
• Anti-Human Thymocyte Immunoglobulin, Rabbit updates RSS · CI watch RSS
• Peking Union Medical College Hospital portfolio CI

Frequently asked questions about Anti-Human Thymocyte Immunoglobulin, Rabbit

Related

• Drug class: All Polyclonal antithymocyte immunoglobulin drugs
• Target: All drugs targeting Human thymocytes and T lymphocyte surface antigens (CD2, CD3, CD4, CD8, HLA-DR)
• Manufacturer: Peking Union Medical College Hospital — full pipeline
• Therapeutic area: All drugs in Immunology
• Indication: Drugs for Prevention of acute organ rejection in allogeneic transplantation
• Indication: Drugs for Treatment of aplastic anemia
• Indication: Drugs for Graft-versus-host disease (GVHD) prophylaxis and treatment
• Also known as: ATG
• Compare: Anti-Human Thymocyte Immunoglobulin, Rabbit vs similar drugs
• Pricing: Anti-Human Thymocyte Immunoglobulin, Rabbit cost, discount & access